Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.
Boyd MA, Carr A, Ruxrungtham K, Srasuebkul P, Bien D, Law M, Wangsuphachart S, Krisanachinda A, Lerdlum S, Lange JM, Phanuphak P, Cooper DA, Reiss P. Boyd MA, et al. Among authors: phanuphak p. J Infect Dis. 2006 Sep 1;194(5):642-50. doi: 10.1086/505709. Epub 2006 Jul 18. J Infect Dis. 2006. PMID: 16897663
Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K. Nuesch R, et al. Among authors: phanuphak p. Clin Infect Dis. 2005 Mar 1;40(5):728-34. doi: 10.1086/427878. Epub 2005 Feb 4. Clin Infect Dis. 2005. PMID: 15714420 Clinical Trial.
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
Boyd MA, Srasuebkul P, Khongphattanayothin M, Ruxrungtham K, Hassink EA, Duncombe CJ, Ubolyam S, Burger DM, Reiss P, Stek M Jr, Lange J, Cooper DA, Phanuphak P. Boyd MA, et al. Among authors: phanuphak p. Antivir Ther. 2006;11(2):223-32. Antivir Ther. 2006. PMID: 16640103 Clinical Trial.
Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).
Boyd MA, Dixit NM, Siangphoe U, Buss NE, Salgo MP, Lange JM, Phanuphak P, Cooper DA, Perelson AS, Ruxrungtham K. Boyd MA, et al. Among authors: phanuphak p. J Infect Dis. 2006 Nov 1;194(9):1319-22. doi: 10.1086/508291. Epub 2006 Sep 25. J Infect Dis. 2006. PMID: 17041859 Clinical Trial.
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM, Phanuphak P. Cardiello PG, et al. Among authors: phanuphak p. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):464-70. doi: 10.1097/00042560-200204150-00006. J Acquir Immune Defic Syndr. 2002. PMID: 11981362 Clinical Trial.
428 results